These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29028765)

  • 1. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer.
    Goldberg H; Klaassen Z; Chandrasekar T; Fleshner N
    Curr Opin Urol; 2018 Jan; 28(1):46-54. PubMed ID: 29028765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance for low-risk prostate cancer: an update.
    Lawrentschuk N; Klotz L
    Nat Rev Urol; 2011 Apr; 8(6):312-20. PubMed ID: 21519351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic challenges of clonal heterogeneity in prostate cancer.
    Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
    J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.
    Fradet V; Toren P; Nguile-Makao M; Lodde M; Lévesque J; Léger C; Caron A; Bergeron A; Ben-Zvi T; Lacombe L; Pouliot F; Tiguert R; Dujardin T; Fradet Y
    BJU Int; 2018 Mar; 121(3):399-404. PubMed ID: 28972698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active surveillance for prostate cancer.
    Romero-Otero J; García-Gómez B; Duarte-Ojeda JM; Rodríguez-Antolín A; Vilaseca A; Carlsson SV; Touijer KA
    Int J Urol; 2016 Mar; 23(3):211-8. PubMed ID: 26621054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations.
    Giganti F; Kirkham A; Allen C; Punwani S; Orczyk C; Emberton M; Moore CM
    AJR Am J Roentgenol; 2021 Apr; 216(4):943-951. PubMed ID: 32755219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
    Chu K; Corcoran N; Norden S; Wong LM
    Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up.
    Ha JY; Shin TJ; Jung W; Kim BH; Park CH; Kim CI
    Investig Clin Urol; 2017 May; 58(3):164-170. PubMed ID: 28480341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.
    Wang JH; Downs TM; Jason Abel E; Richards KA; Jarrard DF
    Curr Urol Rep; 2017 Jul; 18(7):48. PubMed ID: 28589399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
    Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM
    Future Oncol; 2018 Dec; 14(29):3073-3083. PubMed ID: 30107751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging Characteristics of Prostate Cancer Patients Who Discontinued Active Surveillance on 3-T Multiparametric Prostate MRI.
    Habibian DJ; Liu CC; Dao A; Kosinski KE; Katz AE
    AJR Am J Roentgenol; 2017 Mar; 208(3):564-569. PubMed ID: 28075651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI and surveillance.
    Ouzzane A; Puech P; Villers A
    Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining 'progression' and triggers for curative intervention during active surveillance.
    Klotz L
    Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 5-alpha-reductase inhibitors in active surveillance.
    Margel D; Fleshner N
    Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
    Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
    Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.